UBS Group’s ProMIS Neurosciences PMN Stock Holding History

UBS Group’s Portfolio PMN Stock Details PMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.09K	Sell	691 -609	-47%	-$6.61K	﹤0.01%	8622
2026 Q1	$16.5K	Sell	1,300 -150	-10%	-$2.24K	﹤0.01%	8073
2025 Q4	$9.9K	Buy	1,450 +1,350	+1,350%	+$13.2K	﹤0.01%	8254
2025 Q3	$1.06K	Buy	+100	New	+$1.38K	﹤0.01%	9443
2024 Q2	–	Sell	-10	Closed	-$478	–	9959
2024 Q1	$478	Sell	10 -227	-96%	-$11.2K	﹤0.01%	8528
2023 Q4	$6.82K	Buy	237 +233	+5,825%	+$8.71K	﹤0.01%	7670
2023 Q3	$204	Sell	4 -24	-86%	-$1.56K	﹤0.01%	8705
2023 Q2	$2.73K	Buy	+28	New	+$3.72K	﹤0.01%	7709
2023 Q1	–	Sell	-94	Closed	-$10.2K	–	10196
2022 Q4	$10.2K	Sell	94 -22	-19%	-$3.08K	﹤0.01%	8562
2022 Q3	$18K	Buy	+116	New	+$17.1K	﹤0.01%	7533

Other funds holding PMN

Jupiter Topco New York $245B AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ABG

Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Yu Fan $108M AUM 137.54% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

UBS Group's PMN Position: Q2 2026 in Review

UBS Group reduced its ProMIS Neurosciences (PMN) stake by 47% in Q2 2026, selling an estimated $6.61K and leaving 691 shares worth $9.09K. The position accounts for ﹤0.01% of the portfolio, ranked #8622.

UBS Group first reported a position in PMN in Q3 2022 and has held it in 10 quarters since. The position peaked at $18K in Q3 2022. 27 funds tracked by Wall St. Rank hold PMN as of Q2 2026.

UBS Group held 691 shares of ProMIS Neurosciences worth $9.09K as of Q2 2026.
UBS Group sold 609 ProMIS Neurosciences shares in Q2 2026, an estimated $6.61K.
ProMIS Neurosciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8622 holding.
UBS Group first reported a position in ProMIS Neurosciences in Q3 2022 and has held it in 10 quarters since.
UBS Group's ProMIS Neurosciences position peaked at $18K in Q3 2022.
27 funds tracked by Wall St. Rank held ProMIS Neurosciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.